Design and prediction of favorable substitution site in trifluorophenyl-substituted homopiperazine, pyrazoline, triazepane derivatives as dipeptidyl peptidase IV Inhibitors: HQSAR and docking studies
- 6 Downloads
In this study, hologram quantitative structure–activity relationship (HQSAR) and molecular docking studies were performed on a dataset of 108 trifluorophenyl homopiperazine, pyrazoline, and triazepane derivatives as dipeptidyl peptidase IV inhibitors. HQSAR model was obtained using atoms, connection, donor, and acceptor as fragment distinction parameters with fragment size (4–7) using components (q2 = 0.738, r2 = 0.962). Molecular docking study was performed to identify novel potent inhibitors and the important amino acid residues, which formed an interaction with compound 105, were Ser-631, His-741, Tyr-663, Glu-204, Arg-123 and Ala-655 with receptor. These models were used to design new compounds for homopiperazine, pyrazoline, triazepane analogs and the results obtained from this study could be useful for further investigations.
KeywordsHQSAR Fragment size Docking Homopiperazine Pyrazoline Triazepane DPP-IV inhibitors
The authors are thankful to the Head, School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore for providing facilities.
Compliance with ethical standards
Conflict of interest
There are no conflicts of interest.
- Ahn JH, Park WS, Jun MA, Shin MS, Kang SK, Kim KY, Rhee SD, Bae MA, Kim KR, Kim SG, Kim SY, Sohn SK, Kang NS, Lee JO, Lee DH, Cheon HG, Kim SS (2008) Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 18:6525–6529CrossRefGoogle Scholar
- Demuth H, Heins J (1995) Catalytic mechanism of dipeptidyl peptidase-IV. In: dipeptidyl peptidase-IV (CD26) in metabolism and the immune response. Fleischer B, Landes RG (eds) Austin, TX, vol. 3, pp 1–35Google Scholar
- Heritage TW, Lowis DR (1999) Molecular hologram QSAR. In: Rational drug design: novel methodology and practical applications. Oxford University Press, New YorkGoogle Scholar
- Jun MA, Park WS, Kang SK, Kim KY, Kim KR, Rhee SD, Bae MA, Kang NS, Sohn SK, Kim SG, Lee JO, Lee DH, Cheon HG, Kim SS, Ahn JH (2008) Synthesis and biological evaluation of pyrazoline analogues with beta-amino acyl group as dipeptidyl peptidase IV inhibitors. Eur J Med Chem 43:1889–1902CrossRefGoogle Scholar
- Lowis DR (1997) HQSAR: a new, highly predictive QSAR technique. Tripos Tech Notes 1(5):17Google Scholar
- Nordhoff S, López-Canet M, Hoffmann-Enger B, Bulat S, Cerezo-Gálvez S, Hill O, Rosenbaum C, Rummey C, Thiemann M, Matassa VG, Edwards PJ, Feurer A (2009) From lead to preclinical candidate optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett 19:4818–4823CrossRefGoogle Scholar
- Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA (2002) Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51(4):943–950CrossRefGoogle Scholar
- Saqib U, Siddiqi MI (2009) 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents SAR QSAR. Environ Res 20:519–535Google Scholar